1161931-71-0 Usage
Uses
Used in Pharmaceutical Research:
(2R,4R)-1-BOC-2-hydroxymethyl-4-amino Pyrrolidine-HCl is used as a building block for the synthesis of more complex molecules in the pharmaceutical industry. Its unique structure and functional groups make it a valuable intermediate in the development of new drugs and therapeutic agents. The BOC protective group can be selectively removed under mild conditions, allowing for further functionalization and modification of the molecule, while the hydroxymethyl and amino groups provide opportunities for conjugation and interaction with other molecules. This versatility makes it a promising candidate for various applications in drug discovery and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1161931-71-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,1,9,3 and 1 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1161931-71:
(9*1)+(8*1)+(7*6)+(6*1)+(5*9)+(4*3)+(3*1)+(2*7)+(1*1)=140
140 % 10 = 0
So 1161931-71-0 is a valid CAS Registry Number.
1161931-71-0Relevant articles and documents
MINERALOCORTICOID RECEPTOR ANTAGONIST AND METHODS OF USE
-
Page/Page column 25, (2010/10/03)
The present invention provides a compound of the formula: Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treati
MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE
-
Page/Page column 22, (2009/07/10)
The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.